OFFICE MANAGEMENT OF OZURDEX IMPLANT DISLOCATION INTO THE ANTERIOR CHAMBER

Retin Cases Brief Rep. 2023 Mar 1;17(2):170-172. doi: 10.1097/ICB.0000000000001140.

Abstract

Purpose: To describe a novel office procedure that permits the repositioning of an Ozurdex implant from the anterior chamber back into the vitreous cavity.

Methods: Description of an office technique for Ozurdex repositioning using a 30-gauge needle.

Results: In both cases, the Ozurdex implant was successfully returned to the vitreous cavity. In Case 1, the patient's visual acuities 1 and 2 weeks after this were 20/70 and 20/40, respectively, and had no further complications. In Case 2, the patient returned 1 week later, with the implant remaining posterior and a visual acuity of 20/40.

Conclusion: The success of this novel technique in these cases demonstrates the potential to avoid a surgical procedure in the event of Ozurdex implant migration to the anterior chamber, while at the same time allowing the Ozurdex implant to remain effective in the eye.

MeSH terms

  • Anterior Chamber / surgery
  • Dexamethasone
  • Drug Implants
  • Foreign-Body Migration* / surgery
  • Glucocorticoids
  • Humans
  • Macular Edema* / complications
  • Office Management

Substances

  • Dexamethasone
  • Glucocorticoids
  • Drug Implants